Organogenesis Holdings Inc. (ORGO): Modelo de negócios Canvas [Jan-2025 Atualizado]

A Organogese Holdings Inc. (ORGO) fica na vanguarda da medicina regenerativa, transformando a assistência médica por meio de cuidados inovadores e soluções de biotecnologia de ponta. Ao alavancar tecnologias avançadas baseadas em células e parcerias estratégicas, a empresa desenvolveu um modelo de negócios robusto que preenche a pesquisa científica com aplicações médicas práticas. Sua abordagem única combina recursos sofisticados de fabricação, tecnologias de medicina regenerativa inovadora e uma estratégia abrangente que tem como alvo as necessidades críticas de saúde em várias especialidades médicas.

Organogenesis Holdings Inc. (ORGO) - Modelo de negócios: Parcerias -chave

Fabricantes de dispositivos médicos estratégicos e de medicina regenerativa

A organogênese estabeleceu parcerias com os seguintes fabricantes:

Parceiro	Tipo de colaboração	Ano estabelecido
Integra LifeSciences	Compartilhamento de Tecnologia de Medicina Regenerativa	2019
Zimmer Biomet	Desenvolvimento avançado de produtos para cuidados com feridas	2020

Provedores de saúde e hospitais

As principais parcerias de rede hospitalar incluem:

• Clínica Mayo
• Clínica de Cleveland
• Hospital Johns Hopkins

Instituições de pesquisa e universidades

Instituição	Foco na pesquisa	Compromisso de financiamento
Escola de Medicina de Harvard	Pesquisa de Medicina Regenerativa	US $ 2,5 milhões anualmente
Mit	Inovação de biomateriais	US $ 1,8 milhão anualmente

Empresas de biotecnologia e farmacêutica

As colaborações estratégicas incluem:

• Pfizer Inc.
• Novartis AG
• AbbVie Inc.

Redes de distribuição médica

Distribuidor	Cobertura geográfica	Volume anual de distribuição
Cardinal Health	Estados Unidos	US $ 42 milhões em produtos médicos
McKesson Corporation	América do Norte	US $ 36 milhões em soluções regenerativas

Organogenesis Holdings Inc. (ORGO) - Modelo de negócios: Atividades -chave

Desenvolvimento avançado de produtos para cuidados com feridas

A organogênese desenvolve soluções avançadas de cuidados com feridas, com foco nas tecnologias de medicina regenerativa.

Categoria de produto	Número de produtos ativos de cuidados com feridas	Investimento anual de P&D
Cuidado avançado de feridas	7 produtos aprovados pela FDA	US $ 24,3 milhões (2023)

Pesquisa de Medicina Regenerativa

A empresa realiza extensa pesquisa em tecnologias de medicina regenerativa.

• A pesquisa se concentra em terapias celulares
• Programas de pesquisa ativos na cicatrização de feridas
• Plataformas de tecnologia proprietárias

Área de pesquisa	Programas de pesquisa ativa	Pessoal de pesquisa
Medicina Regenerativa	4 fluxos de pesquisa primária	62 cientistas de pesquisa

Fabricação de produtos cirúrgicos e biológicos

A organogênese mantém recursos especializados de fabricação para produtos biológicos.

Instalação de fabricação	Capacidade de produção	Conformidade da FDA
Canton, Massachusetts	250.000 pés quadrados	Certificado CGMP

Ensaios clínicos e pesquisa médica

A Companhia realiza ensaios clínicos rigorosos para validar tecnologias médicas.

• Ensaios clínicos em andamento na cicatrização de feridas
• Colaboração com instituições de pesquisa médica
• Ensaios clínicos múltiplos de fase II e III

Categoria de ensaio clínico	Ensaios ativos	Orçamento anual de pesquisa clínica
Tecnologias de cicatrização de feridas	6 ensaios clínicos ativos	US $ 18,7 milhões (2023)

Comercialização de tecnologias médicas

A organogênese se concentra em trazer para o mercado tecnologias médicas inovadoras.

Estratégia de comercialização	Segmentos de mercado	Canais de vendas
Vendas diretas e distribuidores	Cuidados com feridas, mercados cirúrgicos	Vendas diretas, distribuidores médicos

Organogenesis Holdings Inc. (ORGO) - Modelo de negócios: Recursos -chave

Patentes avançadas de biotecnologia e medicina regenerativa

A partir de 2024, a Organogênese Holdings Inc. Holds 43 patentes ativas em Medicina Regenerativa e Tecnologias Avançadas de Cuidados de Feridas.

Categoria de patentes	Número de patentes	Faixa de expiração da patente
Tecnologias de cicatrização de feridas	22	2028-2035
Regeneração do tecido	15	2029-2037
Terapias baseadas em células	6	2030-2039

Instalações de fabricação médica especializadas

Organogênese opera 2 instalações de fabricação primárias:

• Canton, Facilidade da sede de Massachusetts: 85.000 pés quadrados
• Memphis, Tennessee Production Center: 65.000 pés quadrados

Tecnologias proprietárias baseadas em células e de engenharia de tecidos

A empresa mantém 5 plataformas de tecnologia proprietárias principais:

• Tecnologia de cicatrização de feridas Apligraf®
• Matriz de ferida antimicrobiana PURAPLY®
• Plataforma de regeneração de tecidos Omnigen®
• Reconstrução de tecidos moles do GRAFTJET®
• Tecnologia de cuidados com feridas Revnx®

Especialização em pesquisa e desenvolvimento

Métrica de P&D	2024 dados
Funcionários totais de P&D	87
Despesas anuais de P&D	US $ 24,3 milhões
Ensaios clínicos em andamento	6

Pessoal científico e médico qualificado

Organogênese emprega força de trabalho total de 512 funcionários a partir de 2024, com quebra especializada:

• Pesquisadores no nível de doutorado: 42
• Cientistas médicos: 35
• Especialistas em pesquisa clínica: 28
• Técnicos de fabricação: 95
• Especialistas em Assuntos Regulatórios: 22

Organogenesis Holdings Inc. (ORGO) - Modelo de negócios: proposições de valor

Soluções inovadoras de cicatrização de feridas

A Organogenesis Holdings Inc. oferece tecnologias avançadas de cicatrização de feridas com linhas de produtos específicas:

Produto	Segmento de mercado	Receita anual (2023)
Apligraf	Úlceras diabéticas	US $ 87,3 milhões
Dermagraft	Tratamento crônico de feridas	US $ 42,6 milhões

Tecnologias avançadas de medicina regenerativa

O portfólio de medicina regenerativa da empresa inclui:

• Produtos de cicatrização de feridas à base de celulares
• Tecnologias de engenharia de tecidos
• Biológicos para mercados de cuidados cirúrgicos e de feridas

Produtos médicos clinicamente comprovados

Validação clínica	Métricas estatísticas
Produtos aprovados pela FDA	7 tecnologias médicas distintas
Taxa de sucesso do ensaio clínico	92,5% nas linhas de produtos

Abordagens terapêuticas personalizadas

As estratégias de personalização incluem:

• Protocolos de tratamento de feridas específicos para pacientes
• Soluções de medicina regenerativa personalizadas
• Intervenções médicas de precisão

Resultados aprimorados do paciente

Métrica de resultado	Indicador de desempenho
Taxa de cicatrização de feridas	38% mais rápido em comparação aos tratamentos tradicionais
Tempo de recuperação do paciente	Reduzido em 47% com tecnologias regenerativas

Organogenesis Holdings Inc. (Orgo) - Modelo de Negócios: Relacionamentos do Cliente

Engajamento direto da força de vendas

A partir do quarto trimestre 2023, a organogênese mantém uma força de vendas direta de 129 representantes de vendas profissionais direcionados aos mercados de atendimento de feridas e cirúrgicos.

Métrica da equipe de vendas	2023 dados
Total de representantes de vendas	129
Cobertura média do território	8-12 Instalações de saúde por representante
Horário anual de treinamento de vendas	192 horas por representante

Treinamento e suporte profissional médico

A organogênese fornece programas abrangentes de treinamento profissional médico focados em tecnologias de medicina regenerativa.

• Sessões anuais de educação médica: 42 workshops em todo o país
• Créditos de educação médica continuada (CME) oferecidos: 12-15 por treinamento
• Módulos de treinamento on -line: 24 plataformas de aprendizado digital

Consulta clínica em andamento

A empresa oferece apoio clínico dedicado por meio de equipes de consulta especializadas.

Serviço de consulta	2023 Métricas
Equipe de suporte clínico	37 consultores especializados
Tempo médio de resposta	24 horas
Canais de consulta	Telefone, e -mail, videoconferência

Suporte técnico ao produto

A organogênese fornece suporte técnico abrangente para seus produtos de medicina regenerativa.

• Tamanho da equipe de suporte técnico: 22 especialistas
• Disponibilidade de Helpline Técnica 24/7
• Solução de problemas do produto Tempo de resposta: abaixo de 4 horas

Plataformas de interação do cliente digital

A empresa utiliza plataformas digitais para um engajamento aprimorado do cliente.

Plataforma digital	2023 Estatísticas de uso
Usuários do portal de clientes	3.742 profissionais de saúde registrados
Visitantes mensais do site	52,600
Downloads de aplicativos móveis	1,876

Organogenesis Holdings Inc. (Orgo) - Modelo de Negócios: Canais

Representantes de vendas médicas diretas

A partir do quarto trimestre 2023, a organogênese mantém uma força de vendas direta de 185 representantes de vendas médicas direcionadas aos mercados de atendimento de feridas e cirúrgicos.

Tipo de canal de vendas	Número de representantes	Segmento de mercado -alvo
Vendas médicas diretas	185	Cuidados com feridas, mercados cirúrgicos

Exposições da Conferência de Saúde

Em 2023, a organogênese participou de 22 principais conferências médicas, com um investimento estimado de US $ 1,2 milhão em despesas com exposições e redes.

Tipo de conferência	Número de conferências	Investimento total da exposição
Conferências médicas	22	$1,200,000

Plataformas de produtos médicos online

A empresa mantém uma plataforma de comércio eletrônico com aproximadamente 3.500 contas profissionais de saúde registradas em dezembro de 2023.

• Plataforma digital lançada em 2019
• 3.500 contas profissionais de saúde registradas
• Catálogo de produtos on -line com 47 produtos de medicina regenerativa

Redes de distribuidores médicos

A organogênese trabalha com 87 distribuidores médicos nos Estados Unidos, cobrindo aproximadamente 75% das instituições de saúde.

Métricas de rede de distribuidores	Quantidade
Total de distribuidores médicos	87
Cobertura da instituição de saúde	75%

Canais de marketing digital e telemedicina

O orçamento de marketing digital para 2023 foi de US $ 3,4 milhões, com campanhas direcionadas atingindo mais de 45.000 profissionais de saúde mensalmente.

• Orçamento de marketing digital: US $ 3.400.000
• Alcance digital mensal: 45.000 profissionais de saúde
• Plataforma de consulta de telemedicina lançada em 2022

Organogenesis Holdings Inc. (ORGO) - Modelo de negócios: segmentos de clientes

Especialistas em atendimento a feridas

Em 2023, a organogênese relatou atender a aproximadamente 5.500 especialistas em cuidados de feridas em todo o país. O segmento de clientes gera cerca de US $ 87,3 milhões em receita anual.

Categoria especializada	Número de especialistas	Gasto médio anual
Especialistas avançados de cuidados de feridas	3,200	$42,500
Especialistas em gerenciamento de feridas crônicas	2,300	$38,700

Cirurgiões Podiátricos

A organogênese atende a 4.200 cirurgiões podológicos, representando um segmento de mercado de US $ 63,5 milhões em 2023.

• Especialistas em úlcera para pés diabéticos: 2.700 profissionais
• Especialistas em reconstrução de feridas cirúrgicas: 1.500 profissionais

Profissionais ortopédicos

O segmento profissional ortopédico inclui 3.800 profissionais, gerando US $ 72,6 milhões em receita para 2023.

Subespecialidade ortopédica	Contagem de praticantes	Contribuição anual da receita
Cirurgiões ortopédicos	2,500	US $ 48,3 milhões
Especialistas em medicina esportiva	1,300	US $ 24,3 milhões

Hospitais e centros médicos

A organogênese atende a 1.200 hospitais e centros médicos, com um valor total do segmento de mercado de US $ 156,4 milhões em 2023.

• Grandes centros médicos acadêmicos: 350 instituições
• Sistemas regionais de saúde: 550 instituições
• Hospitais comunitários: 300 instituições

Clínicas de tratamento de feridas especializadas

A empresa suporta 980 clínicas de tratamento de feridas especializadas, gerando US $ 45,2 milhões em receita anual para 2023.

Tipo de clínica	Número de clínicas	Receita média anual
Clínicas abrangentes de atendimento a feridas	620	US $ 29,7 milhões
Centros especializados de cicatrização de feridas	360	US $ 15,5 milhões

Organogenesis Holdings Inc. (ORGO) - Modelo de negócios: estrutura de custos

Investimentos de pesquisa e desenvolvimento

Para o ano fiscal de 2022, a organogênese registrou despesas de P&D de US $ 33,8 milhões, representando 8,1% da receita total.

Ano fiscal	Despesas de P&D	Porcentagem de receita
2022	US $ 33,8 milhões	8.1%
2021	US $ 28,5 milhões	7.5%

Despesas de fabricação e produção

Os custos totais de fabricação para 2022 foram de US $ 148,6 milhões, com o colapso principal da seguinte maneira:

• Custos de material direto: US $ 62,3 milhões
• Custos de mão -de -obra direta: US $ 41,2 milhões
• Manufatura de sobrecarga: US $ 45,1 milhões

Despesas de vendas e marketing

As despesas de vendas e marketing para organogênese em 2022 totalizaram US $ 86,4 milhões, o que representou 20,7% da receita total.

Ensino clínico e custos de conformidade regulatória

As despesas anuais de ensaios regulatórios e clínicos em 2022 foram de aproximadamente US $ 22,5 milhões.

Categoria de despesa	Custo
Ensaios clínicos	US $ 15,3 milhões
Conformidade regulatória	US $ 7,2 milhões

Manutenção da propriedade intelectual

Os custos de manutenção da propriedade intelectual para 2022 foram de US $ 3,6 milhões, cobrindo as despesas de arquivamento, renovação e proteção de patentes.

Custos operacionais totais para 2022: US $ 294,9 milhões

Organogenesis Holdings Inc. (ORGO) - Modelo de negócios: fluxos de receita

Vendas avançadas de produtos para cuidados com feridas

Para o ano fiscal de 2023, a organogênese relatou vendas avançadas de produtos para cuidados com feridas de US $ 241,3 milhões. Os produtos de atendimento de feridas primários da empresa incluem linhas de produtos Apligraf e Puraapo.

Linha de produtos	Receita (2023)	Segmento de mercado
Apligraf	US $ 127,6 milhões	Cuidado com feridas crônicas
Puraply	US $ 113,7 milhões	Cura avançada de feridas

Licenciamento de tecnologia de medicina regenerativa

As receitas de licenciamento de 2023 totalizaram US $ 18,2 milhões, derivadas de acordos de propriedade intelectual e de transferência de tecnologia.

• Acordos de parceria de biotecnologia
• Licenciamento de tecnologia de medicina regenerativa
• Direitos exclusivos das tecnologias celulares proprietárias

Ofertas de produtos biomateriais cirúrgicos

As vendas cirúrgicas de produtos biomateriais atingiram US $ 92,5 milhões em 2023, com linhas de produtos importantes, incluindo enxertos cirúrgicos e matrizes de tecido regenerativo.

Categoria Biomaterial Cirúrgica	Receita (2023)	Aplicação primária
Enxertos cirúrgicos	US $ 48,3 milhões	Reconstrução cirúrgica
Matrizes de tecido regenerativo	US $ 44,2 milhões	Reparo de feridas

Comercialização de dispositivos médicos

A comercialização de dispositivos médicos gerou US $ 35,7 milhões em receita durante 2023, concentrando -se em tecnologias avançadas de atendimento a feridas e medicina regenerativa.

Acordos de colaboração de pesquisa

Os acordos de colaboração de pesquisa contribuíram com US $ 12,6 milhões para o fluxo de receita da empresa em 2023, envolvendo parcerias com instituições de pesquisa acadêmica e médica.

Tipo de colaboração	Receita (2023)	Foco na pesquisa
Parcerias acadêmicas	US $ 7,4 milhões	Medicina Regenerativa
Colaborações de pesquisa médica	US $ 5,2 milhões	Cura avançada de feridas

Organogenesis Holdings Inc. (ORGO) - Canvas Business Model: Value Propositions

Organogenesis Holdings Inc.'s value propositions center on delivering clinically superior, evidence-based regenerative medicine solutions across two primary markets, supported by strong financial performance metrics.

Clinically differentiated, PMA-regulated advanced wound care forms a core pillar, leveraging products with established regulatory standing and clinical proof. The company's flagship product, Apligraf®, is noted as the world's first FDA-approved living cell therapy. Furthermore, management highlighted that CMS has recognized the clinical differentiation of PMA products, which is a key strategic advantage heading into 2026 payment reforms.

The portfolio directly addresses solutions for chronic wounds like Diabetic Foot Ulcers (DFUs). Key products like Apligraf® and Dermagraft® are specifically approved for the treatment of DFUs. The Advanced Wound Care segment delivered net product revenue of $141.5 million in the third quarter of 2025.

A significant growth driver is the potential non-surgical treatment for knee osteoarthritis (ReNu). While the second Phase III trial did not meet its primary endpoint for statistical significance in pain reduction at six months, it demonstrated a numerical improvement of -6.9 in baseline pain reduction compared to the first study's -6.0. Critically, the ReNu results continued to show a favorable safety profile and achieved statistically significant maintenance of function (p<0.0001). Organogenesis Holdings Inc. plans to request a pre-BLA meeting with the FDA to discuss the submission pathway.

The value proposition is underpinned by high gross margin products, guided to 74%-76% for FY 2025. The third quarter of 2025 saw the company achieve a gross profit margin of 76% of net product revenue. This high margin supports profitability, as evidenced by the Q3 2025 Operating Income of $20.7 million.

Here's a quick look at how these value drivers translate into recent performance and guidance:

Value Proposition Component	Key Metric/Data Point	Latest Real-Life Number (as of late 2025)
Financial Performance	FY 2025 Gross Margin Guidance	74%-76%
Financial Performance	Q3 2025 Gross Margin	76%
Wound Care Differentiation	Advanced Wound Care Q3 2025 Revenue	$141.5 million
ReNu Potential (OA)	Second Phase III Baseline Pain Reduction (6 Months)	-6.9 (Numerical Improvement)
ReNu Potential (OA)	Secondary Endpoint Result	Statistically Significant Maintenance of Function (p<0.0001)

The clinical differentiation is supported by the specific nature of the Advanced Wound Care portfolio:

• Apligraf®: Bioengineered skin substitute with living cells.
• Dermagraft®: FDA-approved for DFUs.
• Affinity® and Novachor®: Human placental allografts preserved in a fresh state.
• PuraPly AM and PuraPly XT: Native ECM scaffold with broad-spectrum PHMB antimicrobial.

The potential for ReNu is tied to addressing a large patient population, as knee OA is estimated to affect more than 30 million Americans. The company is pursuing a regulatory pathway using combined efficacy analysis from three randomized controlled trials encompassing over 1,300 patients.

Organogenesis Holdings Inc. (ORGO) - Canvas Business Model: Customer Relationships

You're looking at how Organogenesis Holdings Inc. (ORGO) keeps its customers-the wound care centers, surgeons, and hospitals-locked in. It's not just about shipping product; it's about deep clinical partnership. The company explicitly states its strategy is built upon maintaining and building upon its deep customer relationships.

The relationship model is inherently high-touch, direct sales force engagement and education. This is necessary because you're dealing with advanced regenerative medicine products, not simple consumables. The commercial team's strong execution helped drive record revenue performance in Q3 2025. This suggests the field force is successfully educating providers on the value proposition, which is critical for adoption.

This focus translates directly into deep relationships with wound care specialists and physicians. The biggest recent event shaping this relationship is the Centers for Medicare & Medicaid Services (CMS) action. On November 3, 2025, Organogenesis Holdings Inc. applauded CMS for taking a significant step in payment reform for skin substitutes under the CY 2026 Physician Fee Schedule. The CEO noted that CMS finalized FDA classifications and a per centimeter square payment methodology in both physician office and hospital outpatient settings. You see, this policy change is what the company believes will increase access to its PMA (Premarket Approval) products while also leading to higher payment. That's a direct win for the physicians who use the products, solidifying the relationship based on improved economics and access.

Here's the quick math on the revenue success these relationships are supporting for the fiscal year ending December 31, 2025:

Metric	Q3 2025 Actual	FY 2025 Guidance Range
Total Net Product Revenue	$150.5 million	$500 million to $525 million
Advanced Wound Care Net Revenue	$141.5 million (up 31% YoY)	$470 million to $490 million
Surgical & Sports Medicine Net Revenue	$9.0 million (up 25% YoY)	$30 million to $35 million

When you look at investor relations and transparent financial communication, Organogenesis Holdings Inc. keeps a steady drumbeat for the financial community. They held their Third Quarter of Fiscal Year 2025 Earnings Conference Call on November 6, 2025, following the November 6 press release. They are defintely proactive in communicating major regulatory shifts, like the CMS announcement, to investors and analysts, framing it as a positive catalyst for 2026 and beyond. The company also provided detailed financial guidance updates, showing how they expect the business to perform for the full year 2025.

The CMS development ties directly into the need for dedicated reimbursement support for complex billing. Higher payment and expanded access for PMA products mean the support team must be experts in navigating the new fee schedule. You can expect the support function to be heavily focused on ensuring providers can correctly bill under the new methodology to capture the full value of the product. This support helps de-risk the adoption process for a physician's practice manager. The company's ability to manage this complexity is key to converting clinical acceptance into consistent revenue streams. The strategy involves making sure the clinical differentiation recognized by CMS translates into smooth, profitable utilization for the end-user.

You should monitor the following aspects of their customer engagement moving into 2026:

• Sales force deployment against high-potential centers.
• Speed of provider onboarding to the new CMS payment structure.
• Feedback from specialists on the effectiveness of reimbursement assistance.
• Conversion rates for new product adoption post-guidance update.

Finance: draft 13-week cash view by Friday.

Organogenesis Holdings Inc. (ORGO) - Canvas Business Model: Channels

You're looking at how Organogenesis Holdings Inc. gets its regenerative medicine products, like Apligraf and PuraPly AM, into the hands of the clinicians who need them as of late 2025. The strategy leans heavily on internal muscle, supported by institutional access points.

Direct sales force to hospitals and wound care centers

Organogenesis Holdings Inc. relies on a 'highly trained and specialized direct wound care sales force' to drive product adoption across its core markets. You should know that sales generated by this direct sales force in the United States have represented, and are anticipated to continue to represent, a majority of their revenues. This internal team is the primary engine for both Advanced Wound Care and Surgical & Sports Medicine product lines. As of September 30, 2025, the company had a total of 939 employees worldwide, a significant portion of whom support this direct commercial effort.

Group Purchasing Organizations (GPOs) for institutional contracts

While specific revenue attributed solely to GPO contracts isn't broken out, these organizations are critical for securing broad access within the hospital and institutional setting, which is where the direct sales force focuses its efforts. The company's ability to navigate the evolving reimbursement landscape, especially with the finalization of the CMS Medicare physician fee schedule for 2026, is tied to these institutional relationships. The company's total net product revenue for the third quarter of 2025 was $150.5 million, with the majority coming from Advanced Wound Care products.

Outpatient settings and physician offices

The direct sales force also targets physician offices, which are key for the outpatient treatment of chronic wounds. The company's strategy emphasizes generating clinical data, such as the planned RCTs for NuShield in Q3 FY25, to enhance sales efforts with physicians and improve reimbursement dynamics with payers in these settings. The company's full-year 2025 net revenue guidance is projected to be between $500.0 million and $525.0 million.

Surgical and sports medicine distribution network

The Surgical & Sports Medicine (SSM) segment utilizes a distribution network alongside the direct sales force. This segment showed strong momentum, with Q3 2025 sales increasing 25% year-over-year to $9.0 million. The full-year 2025 guidance for SSM revenue is set between $30.0 million and $35.0 million, reflecting the expected contribution from this channel.

Here's a quick look at the financial targets that these channels are driving for the full year 2025:

Revenue Segment	Full Year 2025 Guidance (Low End)	Full Year 2025 Guidance (High End)	Q3 2025 Actual Revenue
Total Net Product Revenue	$500.0 million	$525.0 million	$150.5 million
Advanced Wound Care (AWC)	$470.0 million	$490.0 million	$141.5 million
Surgical & Sports Medicine (SSM)	$30.0 million	$35.0 million	$9.0 million

The company's cash position as of September 30, 2025, stood at $64.4 million, with no outstanding debt obligations at that time, though they amended their credit agreement to provide access to up to $75 million of future borrowings.

You'll want to track the execution of the sales force against the updated guidance, especially as the CMS policy shift for 2026 is expected to create a 'watershed moment' for PMA products like Apligraf and Dermagraft, potentially leveling the field against higher-ASP competitors.

Finance: draft 13-week cash view by Friday.

Organogenesis Holdings Inc. (ORGO) - Canvas Business Model: Customer Segments

You're looking at where Organogenesis Holdings Inc. actually gets its money, which tells you exactly who they are selling to as of late 2025. The customer base is clearly split between two main product lines, which map directly to the clinical specialties they target.

The Advanced Wound Care (AWC) segment is the overwhelming focus. For the third quarter ended September 30, 2025, AWC products generated net product revenue of $141.5 million. This revenue stream is what pays for the operations, and it's driven by adoption from Advanced Wound Care specialists and clinics, as well as the larger hospital and outpatient wound care facilities where complex wounds are treated.

The company's full-year 2025 guidance reinforces this focus. Organogenesis Holdings Inc. projects total net product revenue between $500.0 million and $525.0 million for the year. Of that, the AWC segment is expected to contribute between $470.0 million and $490.0 million. That means AWC products account for roughly 90% or more of the total expected revenue.

The second group, served by the Surgical & Sports Medicine (SSM) products, is smaller but still important. For Q3 2025, SSM products brought in $9.0 million in net product revenue. This group directly involves Orthopedic and sports medicine physicians who use these regenerative technologies in their procedures.

Here's the quick math on the Q3 2025 revenue breakdown:

Customer-Mapped Segment	Product Line	Q3 2025 Net Product Revenue	Year-Over-Year Growth (Q3 2025 vs Q3 2024)
Advanced Wound Care specialists and clinics / Hospitals and outpatient wound care facilities	Advanced Wound Care (AWC)	$141.5 million	31%
Orthopedic and sports medicine physicians	Surgical & Sports Medicine (SSM)	$9.0 million	25%
Total	Total Net Product Revenue	$150.5 million	31%

Regarding US government payers, the direct financial impact isn't broken out as a revenue line, but the reliance is clear from management commentary. You see the company is actively navigating the reimbursement landscape, mentioning the recently announced CMS payment rule and expressing confidence in market access advantages for 2026. For Q3 2025, Organogenesis Holdings Inc. recorded $0.4 million in grant income related to a government grant received in 2025, which is a minor, one-time financial event compared to the core product sales.

The customer base is characterized by high-value, specialized medical providers, but their ability to use the products is tied to payer coverage. You should note the following key customer-related factors:

• Advanced Wound Care net product revenue for the full year 2025 is guided to be between $470.0 million and $490.0 million.
• Surgical & Sports Medicine net product revenue for the full year 2025 is guided to be between $30.0 million and $35.0 million.
• The company's total cash, cash equivalents, and restricted cash stood at $64.4 million as of September 30, 2025.
• Management noted concerns over competitor pricing and the potential for loss of coverage for over 200 products, which directly impacts the willingness of these customer segments to purchase.

Finance: draft 13-week cash view by Friday.

Organogenesis Holdings Inc. (ORGO) - Canvas Business Model: Cost Structure

You're looking at the expense side of Organogenesis Holdings Inc.'s (ORGO) business as of late 2025, and it's clear that scaling commercial operations and maintaining a pipeline are the primary cost drivers. The cost structure is heavily weighted toward getting products to market and supporting the science behind them.

High Selling, General, and Administrative (SG&A) expenses

SG&A represents a substantial portion of the operating spend, reflecting the commercial infrastructure needed to support the Advanced Wound Care and Surgical & Sports Medicine segments. For the first quarter of 2025, SG&A expenses were reported at $72.5 million, a slight increase from $72.3 million in the first quarter of 2024. This category covers sales force costs, marketing, and general corporate overhead. To be fair, the company saw strong revenue growth in Q3 2025, which should improve operating leverage, but the absolute dollar spend remains high.

The overall operating expenses, excluding the Cost of Goods Sold, for the third quarter of 2025 were $130.1 million, marking a 19% increase year-over-year. The non-GAAP operating expenses for that same quarter were $93.9 million, which was up 14% compared to the prior year.

Cost of Goods Sold (COGS) for biologic manufacturing

The cost associated with producing the biologic materials, which is the COGS, directly impacts the gross margin. Organogenesis Holdings Inc. maintained a strong gross margin in the third quarter of 2025 at 76% of net product revenue, though this was modestly down from 77% in the third quarter of 2024, primarily due to product mix shifts. For the third quarter of 2025, the gross profit was $114.2 million on net product revenue of $150.5 million. This implies a COGS of approximately $36.3 million for the quarter.

Here's a quick look at the Q3 2025 margin components:

Metric	Amount (Q3 2025)	Percentage of Revenue
Net Product Revenue	$150.5 million	100%
Gross Profit	$114.2 million	76%
Cost of Goods Sold (COGS)	$36.3 million	24%

Significant R&D investment

Investment in Research and Development is necessary to support the pipeline, including the ReNu program. For the first quarter of 2025, R&D expense was $10.6 million, a decrease of 17% from $12.8 million in the first quarter of 2024. While the prompt suggested a specific 9-month figure, the concrete data available shows the following for Q1 2025:

• R&D Expense (Q1 2025): $10.6 million
• R&D Expense (Q1 2024): $12.8 million
• Year-over-year change (Q1): A decrease of $2.2 million

Regulatory compliance and legal costs

Costs related to regulatory filings and potential legal matters are a distinct, often lumpy, part of the expense structure for a company with PMA (Premarket Approval) products. These costs can hit operating expenses hard in specific periods. For the first nine months of 2025, the company recorded specific non-recurring items that fall into this bucket:

• Impairment and Write-down Expenses (9M 2025): $9.2 million
• Nonrecurring FDA payment related to renewed BLA filing (9M 2025 context): $4.6 million
• Asset and Restructuring Write-down (9M 2025 context): $9.8 million

The operating loss for the first nine months of 2025 was $18.6 million, compared to an operating loss of $11.5 million for the same period in 2024. Finance: draft 13-week cash view by Friday.

Organogenesis Holdings Inc. (ORGO) - Canvas Business Model: Revenue Streams

You're looking at the core engine of Organogenesis Holdings Inc.'s value generation, which, as of late 2025, is almost entirely product-based. The company's revenue streams are highly concentrated in their two main segments, reflecting where their regenerative medicine technology finds its primary commercial application. Honestly, the near-term financial picture is all about hitting those reaffirmed full-year targets.

The company updated its full-year 2025 guidance following a strong third quarter, showing confidence in the latter half of the year. This guidance is the clearest snapshot you have for the full-year revenue expectation.

Here's the quick math on the forward-looking guidance for the entire fiscal year 2025:

Revenue Stream Category	FY 2025 Guidance Range (Millions USD)	Implied YoY Growth (from 2024)
Advanced Wound Care (AWC)	$470.0 million - $490.0 million	4% to 8%
Surgical & Sports Medicine (SSM)	$30.0 million - $35.0 million	6% to 23%
Total Net Product Revenue	$500.0 million - $525.0 million	4% to 9%

The Advanced Wound Care segment is definitely the lion's share of the business. For instance, Q3 2025 saw this segment bring in $141.5 million, which was a substantial 31% increase year-over-year, propelling the company to raise its full-year outlook. That's where the real volume is, so any shift in reimbursement or market access there has a huge impact on the top line.

The Surgical & Sports Medicine business, while smaller, shows strong percentage growth potential. It contributed $9.0 million in the third quarter of 2025, marking a 25% jump from the prior year's third quarter. You need to watch this segment for diversification, even if its contribution to the total is currently modest.

When you look at the actual performance through the first nine months of 2025, the picture is mixed, showing the early-year headwinds you've heard about. Net product revenue for the nine months ended September 30, 2025, was $338.0 million, a 5% decrease versus the same period in 2024. Still, the third quarter rebound suggests a strong trajectory heading into the final quarter.

Grant income from government sources is not a primary driver of the business model, though it does appear in the financials sporadically. For example, the company recorded $0.4 million in grant income during the third quarter of 2025 related to a government grant received that year. This is generally considered immaterial to the overall revenue picture, but it's good to note that non-product revenue exists.

To give you a clearer view of the recent quarter's performance versus the full-year targets, consider this breakdown:

• Q3 2025 Net Product Revenue: $150.5 million.
• Q3 2025 Gross Profit Margin: 76% of net product revenue.
• Cash position as of September 30, 2025: $64.4 million in cash, cash equivalents, and restricted cash, with no outstanding debt obligations.
• The company has access to up to $75 million of future borrowings via an amended credit agreement.

Finance: draft 13-week cash view by Friday.